EPHX2 and metabolic dysfunction-associated steatotic liver disease: In this review, we summarize the novel field of sEH inhibition in liver diseases by analyzing preclinical studies in several liver pathologies including NAFLD and associated metabolic disorders, NASH, and PTH.